

Temilolu Idowu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7939360/publications.pdf>

Version: 2024-02-01

17
papers

835
citations

758635

12
h-index

887659

17
g-index

17
all docs

17
docs citations

17
times ranked

1177
citing authors

#	ARTICLE	IF	CITATIONS
1	Ursane-Type Triterpenes, Phenolics and Phenolic Derivatives from <i>Globimetula braunii</i> Leaf. <i>Molecules</i> , 2021, 26, 6528.	1.7	4
2	Overcoming β -Lactam resistance in <i>Pseudomonas aeruginosa</i> using non-canonical tobramycin-based antibiotic adjuvants. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127575.	1.0	11
3	A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> and Delays Resistance Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	11
4	Syntheses of l-Rhamnose-Linked Amino Glycerolipids and Their Cytotoxic Activities against Human Cancer Cells. <i>Molecules</i> , 2020, 25, 566.	1.7	6
5	Development of a nebramine-cyclam conjugate as an antibacterial adjuvant to potentiate β -lactam antibiotics against multidrug-resistant <i>P. aeruginosa</i> . <i>Journal of Antibiotics</i> , 2019, 72, 816-826.	1.0	15
6	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9103-9115.	2.9	24
7	Potential of β -lactam antibiotics and β -lactam/ β -lactamase inhibitor combinations against MDR and XDR <i>Pseudomonas aeruginosa</i> using non-ribosomal tobramycin-cyclam conjugates. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2640-2648.	1.3	30
8	Amphiphilic nebramine-based hybrids Rescue legacy antibiotics from intrinsic resistance in multidrug-resistant Gram-negative bacilli. <i>European Journal of Medicinal Chemistry</i> , 2019, 175, 187-200.	2.6	19
9	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of <i>Pseudomonas aeruginosa</i> to doxycycline and chloramphenicol <i>in vitro</i> and in a <i>Galleria mellonella</i> <i>in vivo</i> model. <i>European Journal of Medicinal Chemistry</i> , 2019, 174, 16-32.	2.6	27
10	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2019, 79, 271-289.	4.9	274
11	Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	5.7	218
12	Replacing d-Glucosamine with Its l-Enantiomer in Glycosylated Antitumor Ether Lipids (GAELs) Retains Cytotoxic Effects against Epithelial Cancer Cells and Cancer Stem Cells. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2142-2147.	2.9	13
13	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3684-3702.	2.9	71
14	Amphiphilic Modulation of Glycosylated Antitumor Ether Lipids Results in a Potent Triamino Scaffold against Epithelial Cancer Cell Lines and BT474 Cancer Stem Cells. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9724-9738.	2.9	20
15	Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities. <i>Antibiotics</i> , 2017, 6, 26.	1.5	66
16	Design, synthesis and evaluation of cytotoxic properties of bisamino glycosylated antitumor ether lipids against cancer cells and cancer stem cells. <i>MedChemComm</i> , 2016, 7, 2100-2110.	3.5	10
17	Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)-chlorambucil-hybrids. <i>Chemistry and Physics of Lipids</i> , 2016, 194, 139-148.	1.5	16